Let's Talk Alzheimer's

BrightFocus Foundation
  • 0,0 (0)
  • Medicin

Welcome to Let’s Talk Alzheimer’s, your place to go for trusted insights from leading scientists and medical experts. Get the latest information on diagnosis, risk reduction, clinical trials, and the latest treatments. Presented by BrightFocus Foundation's Alzheimer's Disease Research program.

Avsnitt

  1. Inside the Alzheimer’s Drug Pipeline: What New Clinical Trials Mean for the Future | Dr. Jeffrey Cummings

    25 juni

    Inside the Alzheimer’s Drug Pipeline: What New Clinical Trials Mean for the Future | Dr. Jeffrey Cummings

    Exciting advances in understanding Alzheimer’s biology, genetics, and biomarkers are driving new medicines, devices, and prevention strategies. In 2025 alone, 182 clinical trials evaluated 138 novel drugs for Alzheimer’s disease. In this episode, leading expert Dr. Jeffrey Cummings from the University of Nevada Las Vegas shares an insider’s look at the rapidly evolving Alzheimer’s treatment pipeline and what today’s clinical trials mean for the future. We also extend our gratitude to the clinical trial participants and families whose involvement makes this critical research possible

    21 min
  2. Lifestyle & Brain Health: U.S. POINTER Study | Dr. Laura D. Baker

    11 juni

    Lifestyle & Brain Health: U.S. POINTER Study | Dr. Laura D. Baker

    Can everyday lifestyle choices really protect your memory? Dr. Laura Baker, professor at Wake Forest University School of Medicine, shares insights from the groundbreaking U.S. POINTER trial—the largest study of its kind exploring how lifestyle changes impact brain health. She breaks down how factors like exercise, nutrition, cognitive engagement, and social connection work together, and what practical steps you can take to reduce your risk of dementia.   For a deeper dive into lifestyle and Alzheimer’s risk, watch our full conversation with Dr. Baker, part of the Zoom In on Dementia and Alzheimer’s series.   Support for Let’s Talk Alzheimer’s is provided by sponsors Lilly, Biogen, Eisai, and Genentech.   Let’s Talk Alzheimer’s is presented by Alzheimer’s Disease Research, a BrightFocus Foundation program. We fund exceptional research across the globe to support the development of cutting-edge treatments, risk reduction strategies, and ultimately a cure for this mind-stealing disease. Visit brightfocus.org to learn more and get involved.

    33 min
  3. Detecting Alzheimer’s: How to Recognize Early Signs | Dr. Sharon Cohen

    11 juni

    Detecting Alzheimer’s: How to Recognize Early Signs | Dr. Sharon Cohen

    Detecting subtle changes in memory or thinking can be unsettling, but understanding what’s behind those changes can lead to critical early diagnosis—or even rule out Alzheimer’s altogether. In this episode, behavioral neurologist Dr. Sharon Cohen, medical director at Toronto Memory Program, explains the early signs and symptoms of Alzheimer’s disease, medical conditions that can mimic dementia, and how to start a conversation with your doctor.   To go deeper, watch our full conversation with Dr. Cohen, part of the Zoom In on Dementia and Alzheimer’s series.   Support for Let’s Talk Alzheimer’s is provided by sponsors Lilly, Biogen, Eisai, and Genentech.   Let’s Talk Alzheimer’s is presented by Alzheimer’s Disease Research, a BrightFocus Foundation program. We fund exceptional research across the globe to support the development of cutting-edge treatments, risk reduction strategies, and ultimately a cure for this mind-stealing disease. Visit brightfocus.org to learn more and get involved.

    43 min
  4. Leqembi & Kisunla: New Alzheimer's Treatments Explained | Dr. Armen J. Moughamian

    11 juni

    Leqembi & Kisunla: New Alzheimer's Treatments Explained | Dr. Armen J. Moughamian

    Just three years ago, there were no FDA-approved treatments that targeted the underlying causes of Alzheimer’s—only medications that modified symptoms. Today, two FDA-approved therapies—Leqembi (lecanemab) and Kisunla (donanemab)—clear amyloid protein from the brain, targeting a potential cause of the disease. Dr. Armen J. Moughamian, a neurologist and medical director of the Ray Dolby Brain Health Center at Sutter Health, joins this episode to answer common questions about what these new therapies can realistically do, including effectiveness, safety, eligibility, infusion logistics, cost, and access.   To learn more, watch our full conversation with Dr. Moughamian, part of the Zoom In on Dementia and Alzheimer’s series.   Support for Let’s Talk Alzheimer’s is provided by sponsors Lilly, Biogen, Eisai, and Genentech.   Let’s Talk Alzheimer’s is presented by Alzheimer’s Disease Research, a BrightFocus Foundation program. We fund exceptional research across the globe to support the development of cutting-edge treatments, risk reduction strategies, and ultimately a cure for this mind-stealing disease. Visit brightfocus.org to learn more and get involved.

    35 min
  • 4 avsnitt

Om

Welcome to Let’s Talk Alzheimer’s, your place to go for trusted insights from leading scientists and medical experts. Get the latest information on diagnosis, risk reduction, clinical trials, and the latest treatments. Presented by BrightFocus Foundation's Alzheimer's Disease Research program.

Information

  • Skapad av
    BrightFocus Foundation
  • Aktiva år
    2 tn
  • Avsnitt
    4
  • Åldersgräns
    Barnvänligt
  • Copyright
    © Copyright 2026 Let's Talk Alzheimer's
  • Programmets webbplats
    Let's Talk Alzheimer's
  • Leverantör

Du kanske också gillar